Revance Therapeutics

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revance Therapeutics excels in Q4 with DAXXIFY approval driving growth

Revance Therapeutics demonstrated strong financial performance and strategic focus in Q4 2022, driven by DAXXIFY sales and revenue growth.
The company's strengths lie in DAXXIFY approval, positive market feedback, and partnerships positioning them well for future growth.
Challenges include competitive dynamics, pricing strategies, and managing increased OpEx, while opportunities exist in market expansion and new product programs.
Overall, Revance is optimistic about their market position and future prospects, emphasizing customer relationships and strategic investments.

Revance Therapeutics posts stellar Q1 results, eyes market expansion

Revance Therapeutics delivered strong Q1 results, driven by robust RHA Collection and DAXXIFY sales, positioning the company for future growth.
While facing challenges in undisclosed market data and paused clinical trials, Revance's strategic focus on market entry and product adoption presents opportunities for expansion.
With a solid cash position, upcoming milestones, and market potential, Revance is poised for continued success in the neuromodulator and therapeutics segments.

Revance Therapeutics reports record revenue growth and strategic expansion

Revance Therapeutics had a robust Q2 2023, marked by strong revenue growth, expanded sales force, and successful marketing efforts.
While facing challenges in market reception and adoption rates for DAXXIFY, the company remains optimistic about driving growth and leveraging opportunities.
With a focus on sales force expansion, product education, and strategic initiatives, Revance is poised for continued commercial progress and success.

Revance Therapeutics reports strong Q3 growth driven by DAXXIFY

Revance Therapeutics is strategically focusing on DAXXIFY launch success, aesthetics growth, and therapeutics opportunities. Despite challenges in account responses and revenue guidance uncertainties, the company remains optimistic about expanding DAXXIFY adoption and maintaining a strong financial position.

Revance Therapeutics reports record revenue, eyes growth in 2024

Revance Therapeutics had a strong performance in 2023, focusing on growth and cost controls for future success.
The company's strategic initiatives and product offerings position it well for continued growth and market expansion.
Challenges in managing expenses and achieving profitability are being addressed with targeted strategies.
Optimism surrounds the potential of DAXXIFY and the company's ability to capitalize on market opportunities.

Revance Therapeutics (RVNC) reports strong Q1 performance and strategic market entry

Revance Therapeutics (RVNC) demonstrated strong performance in Q1 2024, driven by growth in DAXXIFY and RHA filler market share, with a strategic entry into the therapeutic neurotoxin market.
The company's focus on innovation, efficiency, and market expansion presents opportunities for revenue growth and competitive positioning, despite challenges in differentiation and market dynamics.
Efforts to drive product adoption, enhance customer engagement, and optimize operational efficiency underscore Revance's commitment to sustainable financial health and long-term success.
Overall, Revance's Q1 performance reflects positive momentum and strategic initiatives aimed at capitalizing on market opportunities and strengthening its competitive position.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The global Botulinum Toxin market should reach $9.09 billion by 2029. Technically, Revance Therapeutics, Inc.'s DAXXIFY is the first time in over 30 years that a truly innovative neurotoxin has been brought to the aesthetics market.

Carpe Diem, Daxxify: Revance Therapeutic Preps For An Exciting Year

NASHVILLE, Tenn.--( BUSINESS WIRE )--Revance Therapeutics, Inc. (RVNC) today provided an update on its early experience program for DAXXIFY® and its preliminary unaudited fourth quarter and full year 2022 financial results.

Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results

NASHVILLE, Tenn.--( BUSINESS WIRE )--Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia in adults, a chronic and debilitating neurologic condition affecting the muscles of the neck.1 Revance was provided a Prescription Drug User Fee Act (PDUFA) date of August 19, 2023.

Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

NASHVILLE, Tenn.--( BUSINESS WIRE )--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the 34th Annual Piper Sandler Healthcare Conference, taking place November 29-December 1, 2022, in New York City. Chief Executive Officer, Mark J. Foley, is scheduled to present on Tuesday, November 29, at 10:00AM ET.

Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference

FDA approval of DAXXIFY for the treatment of patients with glabellar (frown) lines already obtained by Revance Therapeutics, Inc. A competing drug by the name of BOTOX was estimated to have generated more than $14.6 billion in sales in 2021.

Revance Therapeutics: FDA Approval Of Daxxify Only One Part Of The Journey

Revance to Participate in the Stifel 2022 Healthcare Conference

Revance Therapeutics, Inc. (NASDAQ:RVNC ) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET Company Participants Jessica Serra - Head of Investor Relations & ESG Mark Foley - Chief Executive Officer Dustin Sjuts - President Tobin Schilke - Chief Financial Officer & Principal Accounting Officer Conference Call Participants Chris Shibutani - Goldman Sachs Ken Cacciatore - Cowen David Amsellem - Piper Sandler Stacy Lee - Stifel Justin Phillips - Morgan Stanley Rohit Bhasin - Needham & Company Operator Welcome to the Revance Therapeutics Third Quarter 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.

Revance Therapeutics, Inc. (RVNC) Q3 2022 Earnings Call Transcript

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -37.65% and 0.90%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Tops Revenue Estimates

Received FDA approval for DAXXIFY™ (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines

Revance Reports Third Quarter 2022 Financial Results, Provides Corporate Update

Revance Announces Two Publications in The Aesthetic Surgery Journal That Advance Glabellar Line Injection Technique and Assessment

Revance Therapeutics, Inc. (RVNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Revance Therapeutics, Inc. (RVNC) Expected to Beat Earnings Estimates: Should You Buy?

Revance to Release Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

Revance Submits Supplemental Biologics License Application (sBLA) for DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

AMC Entertainment

Altice USA

Cano Health

Cricut

Eve Holding Inc

Getty Images Holdings Inc

IVERIC bio Inc

NCR Corporation

Sotera Health

Mid-cap stocks are a good choice for investors who are okay with relatively more volatility to get some extra returns.

These Were The Five Best And Worst Performing Mid-Cap Stocks In September 2022

Revance Appoints David A. Hollander, M.D.

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Present Clinical Data on the Efficacy and Safety Profile of DAXXIFY™ for Injection at the 2022 ASDS Annual Meeting

Revance to Present Clinical Data on the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Participate in the Guggenheim Nantucket Therapeutics Conference

Revance to Participate in the Guggenheim Nantucket Therapeutics Conference

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY™ For Injection in the Aesthetic Surgery Journal

Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) For Injection in the Aesthetic Surgery Journal

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Present Data from Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY™ Injection for the Treatment of Upper Limb Spasticity at MDS

Revance to Present Data from Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY™ (DaxibotulinumtoxinA-lanm) Injection for the Treatment of Upper Limb Spasticity at the International Congress of Parkinson and Movement Disorder Society (MDS)

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Revance Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces Pricing of $200.0 Million Upsized Public Offering of Common Stock

Revance Announces Pricing of $200.0 Million Upsized Public Offering of Common Stock

FDA approves Revance Therapeutics' (RVNC) Daxxify as a long-acting neuromodulator with a strong label that includes 36-week efficacy data from the SAKURA clinical program.

Revance (RVNC) Gets FDA Nod for Anti-Wrinkle Product, Stock Up

Revance Therapeutics says its new treatment, Daxxify, diminishes facial wrinkles for up to six months.

Revance Shares Jump 17% After FDA Approves Botox Rival

Revance Therapeutics (NASDAQ: RVNC ) stock is jumping 12% and trending on social media today. The company announced this morning that the Food and Drug Administration (FDA) had approved its alternative to Botox.

Why Is Revance Therapeutics (RVNC) Stock Soaring Today?

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces FDA Approval of DAXXIFY™ for injection, the First and Only Peptide-Formulated Neuromodulator with Long-Lasting Results

Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results

News for Revance Therapeutics Stock (RVNC)